Utilization and Switching Patterns of Mixed Amphetamine Salt (MAS) Products in Patients with Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy: A Descriptive Analysis

In these reports, we examined utilization and switching patterns of mixed amphetamine salt (MAS) products among patients with attention deficit hyperactivity disorder (ADHD) and narcolepsy in the Sentinel Distributed Database (SDD). 

• Report 1: This report contains information on utilization and switching for each Abbreviated New Drug Application (ANDA) grouping of MAS products as well as each grouping of MAS products except for those of a specific ANDA. This report contains information regarding switching to or from an ANDA group other than the one on which the patient started. The study period includes data from January 1, 2013 to December 31, 2019. We distributed this request to five Sentinel Data Partners on November 9, 2021.
• Report 2: This report contains information about the same ANDA groupings, but instead examines switching to any higher strength MAS immediate release (IR) product, regardless of ANDA group. The study period includes data from January 1, 2013 to December 31, 2019. We distributed this request to five Sentinel Data Partners on November 16, 2021.